Other single compounds
|PHA retargeted compounds|
|32442287 2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.|
32588453 2020. Covid-19 and Thymoquinone: Connecting the Dots.
32419212 2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?
32576980 2020. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.
32559419 2020. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.
hzVSF‐v13 Humanized virus suppressing factor‐variant 13 (hzVSF‐v13) is a monoclonal IgG4 against vimentin, which is expressed on the surface of virus‐infected cells.
32458425 2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.
32510814 2020. Omalizumab and COVID19 Treatment: Could It Help? Anti-IgE mab, -IL6,-TNF,-IL1,-NFKB
32505756 2020. Almitrine as a non-ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients.
32505755 2020. Effect of almitrine bismesylate and inhaled nitric oxide on oxygenation in COVID-19 acute respiratory distress syndrome.
32512007 2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.
32327293 ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19
Lauric acid nat. compd.
32318327 ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19
CGRP calcitonin gene related peptide antagonists
32386433 2020. Could CGRP Antagonists Be Helpful in the Fight Against COVID-19?
- 9 retargeted: ternatin4, zotatifin, plitidepsin; haloperidol, melperone, clemastine, cloperastine, pb28, progesterone
- paper in nature
32251767 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)
32495654 2020. Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.
32245264 2020. Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses
32378817 2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients
32362440 ä. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases
32593491 2020. Molecular pharmacology of ciclesonide against SARS-CoV-2.
32402512 2020. A Case of Coronavirus Disease 2019 Treated With Ciclesonide.
32352081 ä. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19
32361169 2020. Why not consider an endothelin receptor antagonist against SARS?CoV?2?
32360293 2020. Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?
Rho kinase inhibitors
32283223 2020. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)
32430287 2020. Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.
32353743 2020. Purposing Saikosaponins for the treatment of COVID-19
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets
ADAM17 as target
32291449 ä. ADAM17 inhibition may exert a protective effect on COVID-19
32405422 2020. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.
32360581 ä. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management
|32312290 2020. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis|
|31856018 2020. Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?|
32427774 2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.
|32427773 2020. Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.|
32275753 ä. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19
32531538 2020. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?
32534337 2020. Diacerein: A potential multi-target therapeutic drug for COVID-19.
32307653 ä. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement
32360140 ä. Bee venom and SARS-CoV-2
32339387 2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin
32519892 2020. Consideration of Pannexin 1 channels in COVID-19 pathology and treatment.
32534944 2020. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.
32347602 2020. Should we try the antiinflammatory natural product, celastrol, for COVID-19?
32352871 2020. A Radiation Mitigator as a Potential Treatment for COVID-19
C7203037 ä. (Vitamin-C; Ozone)Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19?
32462858 2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.
stimulating the Platelets
|32315397 2020. Promoting platelets is a therapeutic option to combat severe viral infection of the lung|
23607598 2013. (x)Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome
32345532 2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.
32429572 2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.
32408699 2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.
32457038 2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.
32416413 2020. Covid-19 management with inflammation resolving mediators? Perspectives and potential
32534226 2020. Monoclonal antibody as a potential anti-COVID-19.
32514101 2020. First antibody against COVID-19 spike protein enters phase I.
32422645 2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
32512271 2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.
32391920 2020. Consider TLR5 for new therapeutic development against COVID-19.
32529963 2020. Can lactoferrin boost human immunity against COVID-19?
32505909 2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
32575350 2020. Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients.
32492560 2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?
|32504751 2020. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.|
32472655 2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.
32505070 2020. Nebulized Lidocaine in COVID-19, An Hypothesis.
32441805 2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin. Methioninase
32503816 2020. Oral Methioninase for Covid-19 Methionine-restriction Therapy.
C7186126 ä. Proposed use of thalidomide for the cytokine storm of COVID-19
32508009 2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.
|32574274 2020. Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing?|
32441764 2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?
P selectin block
32464083 2020. P-selectin blockade in COVID-19-related ARDS.
32574958 2020. Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.
32443911 2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.
32442437 2020. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
Endoplasmic reticulum stress
32454157 2020. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.
32561291 2020. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?
Lysosomes, Autophagy, Membranes
32522674 2020. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.
32522067 2020. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
32521191 2020. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
32425923 2020. Could the Inhibition of Endo-Lysosomal Two-Pore Channels (TPCs) by the Natural Flavonoid Naringenin Represent an Option to Fight SARS-CoV-2 Infection?
32449802 2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?
32342366 2020. Autophagie - ein Ansatzpunkt fur ein Medikament gegen COVID-19? : Kampf gegen das Coronavirus.
32567972 2020. Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway.
32516655 2020. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.
32405226 2020. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.
32431755 2020. The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.
Quarternary ammonium compounds
32451736 2020. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19.
32581194 2020. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?
32569833 2020. Exportin 1 inhibition as antiviral therapy.
32560203 2020. Quinoxaline Derivatives as Antiviral Agents: A Systematic Review.
32575019 2020. Pirfenidone: A novel hypothetical treatment for COVID-19.
32594204 2020. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
32525005 2020. Effective block by pirfenidone, an antifibrotic pyridone compound (5-methyl-1-phenylpyridin-2[H-1]-one), on hyperpolarization-activated cation current: An additional but distinctive target.
32536564 2020. IL-15 immunotherapy is a viable strategy for COVID-19.
32587806 2020. A potential role for Galectin-3 inhibitors in the treatment of COVID-19.
32603531 2020. Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.
32547693 2020. A Role for Metal-Based Drugs in Fighting COVID-19 Infection? The Case of Auranofin.
32384906 2020. Use of triiodothyronine to treat critically ill COVID-19 patients: a new clinical trial.
32594322 2020. Antiviral activity of berberine.
32571773 2020. Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018.
32335281 ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19
|32077621 2020. Glycyrrhizic-Acid-Based Carbon Dots with High Antiviral Activity by Multisite Inhibition Mechanisms|
32458502 2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.
32592716 2020. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?
32574273 2020. Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?
32543164 2020. The comparison of the effectiveness of lincocin(R) and azitro(R) in the treatment of covid-19-associated pneumonia: A prospective study.
Immune checkpoint inhibitors pd1
32544799 2020. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.
32551855 2020. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.
32297520 2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
32551456 2020. Use of Spironolactone in SARS-CoV-2 ARDS Patients.
32513242 2020. Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease.
32554324 2020. Noradrenergic and serotonergic drugs may have opposing effects on COVID-19 cytokine storm and associated psychological effects.
beta adrenergic antagonists
32388480 2020. Can beta-adrenergic blockers be used in the treatment of COVID-19?
alpha1 adrenergic antagonists
32352407 2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists
32237190 ä. What does androgenetic alopecia have to do with COVID?19? An insight into a potential new therapy
32540604 2020. Iodine, a preventive and curative agent in the COVID-19 pandemic?
32600410 2020. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection.